Amgen, Kite Pharma ink deal to develop cancer immunotherapies

(Reuters) – Amgen Inc and Kite Pharma Inc said they entered into a deal to develop and market cancer immunotherapies using Amgen’s cancer targets and Kite’s technology platform. Amgen will pay Kite Pharma $60 million upfront and fund research costs through the filing of a new drug application. After that each company will conduct and fund trials for their therapeutic candidates, they said in a joint statement. …
Go to Source

FDA staff recommends Novartis copy of Amgen’s Neupogen

(Reuters) – Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG’s copy of Amgen Inc’s blockbuster cancer drug Neupogen. Novartis’s drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers found no “clinically meaningful differences” between the two drugs, the FDA said. (http://1.usa.gov/1DoT7eb) The injectable biotech medicine is designed to prevent infections in breast cancer patients undergoing chemotherapy, which reduces white blood cells, giving rise to a condition called neutropenia. …
Go to Source

Liberia plans to reopen schools in February as Ebola spread ebbs

MONROVIA (Reuters) – Liberia plans to reopen schools in February, six months after the government ordered them closed because of the Ebola outbreak that has killed more than 3,400 people in the West African nation, an official said on Monday. The rate of new Ebola cases has slowed in recent weeks in Liberia where the government and international organizations with support from the United States stepped up efforts to stop the spread of the disease. President Ellen Johnson Sirleaf announced at the weekend that schools would reopen on Feb. …
Go to Source

1 335 336 337 338 339 345